MYDA Advisors’s Traws Pharma TRAW Stock Holding History

MYDA Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-507	Closed	-$73K	–	176
2019 Q4	$73K	Buy	+507	New	+$94.7K	0.03%	106

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HWA

Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Quilter Plc London, United Kingdom $5.7B AUM 21.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MYDA Advisors's TRAW Position: Q1 2020 in Review

MYDA Advisors sold out of Traws Pharma (TRAW) in Q1 2020, closing a stake of 507 shares — an estimated $73K sold.

MYDA Advisors first reported a position in TRAW in Q4 2019 and held it in 1 quarter. The position peaked at $73K in Q4 2019. 21 funds tracked by Wall St. Rank hold TRAW as of Q1 2020.

MYDA Advisors reported no remaining Traws Pharma position as of Q1 2020 after selling out during the quarter.
MYDA Advisors sold 507 Traws Pharma shares in Q1 2020, an estimated $73K.
MYDA Advisors first reported a position in Traws Pharma in Q4 2019 and held it in 1 quarter.
MYDA Advisors's Traws Pharma position peaked at $73K in Q4 2019.
21 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.